Daewoong pharmaceutical Co.,Ltd (069620.KS)
KRW 125500.0
(-2.64%)
KRW 125500.0
(-2.64%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 1375.32 Billion | 1280.09 Billion | 1152.97 Billion | 1055.42 Billion | 1113.42 Billion | 1031.42 Billion |
| Cost of Revenue | 693.77 Billion | 641.13 Billion | 608.22 Billion | 608.48 Billion | 635.13 Billion | 621.48 Billion |
| Gross Profit | 681.55 Billion | 638.95 Billion | 544.74 Billion | 446.94 Billion | 478.29 Billion | 409.94 Billion |
| Operating Expenses | 560.43 Billion | 543.16 Billion | 455.84 Billion | 429.96 Billion | 433.6 Billion | 385.37 Billion |
| Selling, General and Administrative Expenses | 225.35 Billion | 245.41 Billion | 215.2 Billion | 207.74 Billion | 215.24 Billion | 167.89 Billion |
| Research and Development Expenses | 145.34 Billion | 163.6 Billion | 127.26 Billion | 115.21 Billion | 109.44 Billion | 113.81 Billion |
| Other Expenses | 104.1 Billion | 134.14 Billion | 113.37 Billion | 106.99 Billion | 108.92 Billion | 3.63 Billion |
| Cost and Expenses | 1254.21 Billion | 1184.29 Billion | 1064.07 Billion | 1038.44 Billion | 1068.73 Billion | 1006.86 Billion |
| Operating Income | 133.4 Billion | 57.09 Billion | 27.6 Billion | 16.97 Billion | 44.68 Billion | 24.56 Billion |
| Interest Expense | 13.6 Billion | 8.4 Billion | 10.24 Billion | 10.6 Billion | 10.08 Billion | 9.59 Billion |
| Income Tax Expense | 1.99 Billion | -833.51 Million | -10.32 Billion | -10.58 Billion | -5.54 Billion | 14.79 Billion |
| Earnings before Tax | 111.63 Billion | 38.32 Billion | 19.93 Billion | 13.55 Billion | 23.32 Billion | -622.52 Million |
| Net Income | 111.5 Billion | 42.23 Billion | 24.5 Billion | 24.14 Billion | 22 Billion | -15.15 Billion |
| Earnings Per Share Basic | 10.65 Thousand | 3815.95 | 2226.87 | 2264.77 | 2132.18 | -1468.08 |
| Earnings Per Share Diluted | 10.65 Thousand | 3815.95 | 2226.87 | 2264.77 | 2132.18 | -1468.00 |
| Weighted Average Shares Outstanding | 11.42 Million | 11.06 Million | 11 Million | 10.66 Million | 10.32 Million | 10.32 Million |
| Weighted Average Shares Outstanding (Diluted) | 11.42 Million | 11.06 Million | 11 Million | 10.66 Million | 10.32 Million | 10.32 Million |
| Gross Margin | 0.50 | 0.50 | 0.47 | 0.42 | 0.43 | 0.40 |
| EBIT Margin | 0.12 | 0.08 | 0.06 | 0.06 | 0.08 | 0.08 |
| Profit Margin | 0.08 | 0.03 | 0.02 | 0.02 | 0.02 | -0.01 |
| EBITDA | 164.91 Billion | 85.12 Billion | 69.07 Billion | 62.93 Billion | 72.05 Billion | 58.95 Billion |
| Earnings Before Tax Margin | 0.10 | 0.04 | 0.02 | 0.02 | 0.04 | 0.02 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 360.54 Billion | 335.78 Billion | 1375.32 Billion | 361.82 Billion | 340.89 Billion | 350.19 Billion |
| Cost of Revenue | 171.88 Billion | 167.27 Billion | 693.77 Billion | 182.36 Billion | 176.02 Billion | 167.07 Billion |
| Gross Profit | 188.66 Billion | 168.51 Billion | 681.55 Billion | 179.45 Billion | 164.87 Billion | 183.11 Billion |
| Operating Expenses | 146.35 Billion | 138.85 Billion | 560.43 Billion | 150.77 Billion | -135.49 Billion | -143.06 Billion |
| Selling, General and Administrative Expenses | 101.12 Billion | 96.71 Billion | - | 105.7 Billion | 135.49 Billion | 143.06 Billion |
| Research and Development Expenses | 44.2 Billion | 40.72 Billion | - | 44.03 Billion | 41.34 Billion | 41.99 Billion |
| Other Expenses | -1.02 Billion | -1.41 Billion | -4.38 Billion | -1.02 Billion | -270.99 Billion | -286.12 Billion |
| Cost and Expenses | 318.23 Billion | 306.12 Billion | 1254.21 Billion | 333.14 Billion | 176.02 Billion | 167.07 Billion |
| Operating Income | 42.31 Billion | 29.66 Billion | 121.11 Billion | 28.68 Billion | 29.38 Billion | 40.05 Billion |
| Interest Expense | - | 4.28 Billion | 13.6 Billion | 3.54 Billion | 3.07 Billion | 3.42 Billion |
| Income Tax Expense | 28.93 Billion | 3.41 Billion | 1.99 Billion | -17.97 Billion | 6.56 Billion | 5.77 Billion |
| Earnings before Tax | 28.39 Billion | 12.46 Billion | 123.64 Billion | 44.83 Billion | 21.81 Billion | 34.52 Billion |
| Net Income | 1.14 Billion | 8.14 Billion | 111.5 Billion | 66 Billion | 15.57 Billion | 24.74 Billion |
| Earnings Per Share Basic | 99.11 | 707.86 | - | 5736.73 | 1353.93 | 2150.33 |
| Earnings Per Share Diluted | 99.11 | 707.86 | - | 5736.73 | 1353.93 | 2150.33 |
| Weighted Average Shares Outstanding | 11.5 Million | 11.5 Million | 11.42 Million | 11.5 Million | 11.5 Million | 11.5 Million |
| Weighted Average Shares Outstanding (Diluted) | 11.5 Million | 11.5 Million | 11.42 Million | 11.5 Million | 11.5 Million | 11.5 Million |
| Gross Margin | 0.52 | 0.50 | 0.50 | 0.50 | 0.48 | 0.52 |
| EBIT Margin | 0.15 | 0.12 | - | 0.11 | 0.48 | 0.52 |
| Profit Margin | 0.00 | 0.02 | 0.08 | 0.18 | 0.05 | 0.07 |
| EBITDA | 54.51 Billion | 41.19 Billion | - | 40.18 Billion | 164.87 Billion | 183.11 Billion |
| Earnings Before Tax Margin | 0.12 | 0.09 | 0.09 | 0.08 | 0.09 | 0.11 |
TCRRF
KHRNF
6054
014580
XELPMOC
300694